ARE YOU WORRIED ABOUT BLEED PROTECTION?

Despite how far we've come, breakthrough bleeds remain

Bleeds that go untreated over time can cause long-term joint damage

David lives with
Hemophilia A

^aA study asked people with hemophilia how many bleeds they had in the last 2 weeks, and then checked if the answers matched what was recorded in their medical records. These results might show that some bleeds are not always reported to the doctor. Limitations of this data may include patient's willingness to report their bleeds, whether patients accurately recalled their number of bleeds, or the correctness of their medical records.

Do you worry about

breakthrough bleeds?

DESPITE ADVANCEMENTS
IN THERAPY

51%

had 1 or more spontaneous bleeds during 18 months of follow up

based on a study of 70 people on non-factor therapy that works like factor 8^b

Every bleed
matters

Joint bleeds can lead to joint damage, long-term pain, reduced mobility, and impact your activities

^bIn a study conducted by the Israeli National Hemophilia Center, 70 people with hemophilia A who had received prophylactic factor 8 mimetic therapy. The study analyzed the number of spontaneous and traumatic bleeds over an 18-month follow-up period.

In another study with factor therapy prophylaxis over the course of a year^c

^cFrom July 2023 to February 2024, people with hemophilia A and their doctors took a survey about managing hemophilia and the challenges with current treatment. In total, 62 doctors and 348 patients with hemophilia A completed the survey. Among the patients with bleeding data of more than 1 year, 28 were using EHL treatment, and 40 were using SHL treatment. This study only included patients receiving hemophilia care, which may not reflect the full range of patient experiences, and since it looks at data from a single point in time, we are unable to observe how health conditions might change over time.

Are you reporting all of your bleeds?

Results show that some bleeds may not be reported to doctors. A study found that people reported more bleeds in a survey than what was recorded in their medical records.^d

Take control of your hemophilia A by talking with your doctor about all bleeds:

Minor bleeds
Joint bleeds
Even a potential microbleed with no clear symptoms

David lives with
Hemophilia A

^dA study asked people with hemophilia how many bleeds they had in the last 2 weeks, and then checked if the answers matched what was recorded in their medical records. These results might show that some bleeds are not always reported to the doctor. Limitations of this data may include patient's willingness to report their bleeds, whether patients accurately recalled their number of bleeds, or the correctness of their medical records.

Your prophylaxis treatment should be

Helping you prevent bleeds

Some people have admitted to limiting activities to reduce bleeds, according to a survey.

Is this true for you? Share your concerns with your care team if you’ve faced similar challenges.

Speak up about your

bleed concerns

Share all of your

breakthrough bleeds

Your voice matters. Tell your doctor about the treatment challenges you are experiencing to take charge of your hemophilia A care.

Teilei and her son Bentlee,
who lives with hemophilia A

TALKING POINTS TO DEEPEN CONVERSATIONS WITH YOUR DOCTOR

In the future, I’m looking to:

Prevent joint bleeds so I have better mobility and less pain
Improve current target joints (a joint that has 3 or more spontaneous bleeds within 6 months)
Have less anxiety and worry about bleeds when planning important activities

Doctor discussion guide

DIFFERENT WAYS TO TREAT HEMOPHILIA today

Factor 8 replacement

Replaces clotting protein that is missing in people with hemophilia A.

The purpose of Factor 8 replacement therapy is to prevent and treat bleeds.

non-factor Therapy that works like factor 8 (also called factor 8 mimetic therapy)

Treatments that work like Factor 8, but don’t replace Factor 8 in the body. By mimicking Factor 8, these treatments help increase the production of thrombin, a protein that plays a crucial role in forming blood clots. It is given with a syringe injection that goes under the skin.

Non-factor therapy that targets anticoagulation inhibition

These treatments block proteins that inhibit clotting, which helps restore the balance between the body's clotting and anticoagulant pathways. Current options are injected subcutaneously (under the skin).

Examples of these treatment approaches include tissue factor pathway inhibitors, activated protein C inhibitors, protein S inhibitors, and antithrombin inhibitors.

Gene therapy

Because hemophilia A is caused by a change in your genes, gene therapy works by providing a new copy of the gene needed to make Factor 8.

Investigating TREATMENTS FOR TOMORROW

Researchers continue to explore different ways to prevent bleeds

While non-factor therapies have improved options for people living with hemophilia A, researchers are still investigating in a few key areas, like:

How therapies work with the clotting cascade: Can they make therapies more effective at helping clots form when needed?

How therapy is administered: Are there ways to make treatments more manageable, like fewer injections or different methods of administration?

How much and how often treatments are dosed: Could therapies be adjusted so you don’t need as many doses or as much product?

Why is this evolution important? Many people desire less frequent dosing, and you may feel the same.

Researchers are also exploring anticoagulation inhibition, which aims to block different proteins to support the body’s natural clotting process. Gene therapy is being studied as a way to provide a new copy of the gene needed to make Factor 8.

These efforts reflect a strong commitment to improving overall care for those living with hemophilia A.